Advanced

Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease?

Ulusoy, Ayse LU and Kirik, Deniz LU (2008) In Experimental Neurology May 3. p.258-260
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by selective degeneration of the dopamine producing neurons in the substantia nigra. There is currently no clinically applicable therapy for treating or preventing Parkinsonian neurodegeneration. Great effort is put behind the development of novel therapeutic approaches that aim to alter the natural progression of the disease. For example, a disease-modifying strategy based on the use of glial cell line-derived neurotrophic factor family of ligands have yielded successful results in animal models and later in initial clinical trials. More recently, identification of the gene mutations underlying the familial forms of the disease opened new frontiers in tackling the... (More)
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by selective degeneration of the dopamine producing neurons in the substantia nigra. There is currently no clinically applicable therapy for treating or preventing Parkinsonian neurodegeneration. Great effort is put behind the development of novel therapeutic approaches that aim to alter the natural progression of the disease. For example, a disease-modifying strategy based on the use of glial cell line-derived neurotrophic factor family of ligands have yielded successful results in animal models and later in initial clinical trials. More recently, identification of the gene mutations underlying the familial forms of the disease opened new frontiers in tackling the underlying neuropathological changes seen in PD brains. Overexpression of parkin, in particular, emerged as a powerful approach with complementary effects to those described with use of neurotrophic factors. In light of the fact that the mechanism of disease in the affected patient population might be significantly variable, the ability to intervene the disease process at multiple levels should be seen as a key point in devising effective treatments. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Experimental Neurology
volume
May 3
pages
258 - 260
publisher
Academic Press
external identifiers
  • wos:000258252000007
  • pmid:18538324
  • scopus:47549084043
ISSN
0014-4886
DOI
10.1016/j.expneurol.2008.04.026
language
English
LU publication?
yes
id
beedd01f-0dba-424a-9c4e-2947b43530dd (old id 1169031)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18538324?dopt=Abstract
date added to LUP
2008-07-03 11:53:56
date last changed
2017-10-01 04:56:53
@article{beedd01f-0dba-424a-9c4e-2947b43530dd,
  abstract     = {Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by selective degeneration of the dopamine producing neurons in the substantia nigra. There is currently no clinically applicable therapy for treating or preventing Parkinsonian neurodegeneration. Great effort is put behind the development of novel therapeutic approaches that aim to alter the natural progression of the disease. For example, a disease-modifying strategy based on the use of glial cell line-derived neurotrophic factor family of ligands have yielded successful results in animal models and later in initial clinical trials. More recently, identification of the gene mutations underlying the familial forms of the disease opened new frontiers in tackling the underlying neuropathological changes seen in PD brains. Overexpression of parkin, in particular, emerged as a powerful approach with complementary effects to those described with use of neurotrophic factors. In light of the fact that the mechanism of disease in the affected patient population might be significantly variable, the ability to intervene the disease process at multiple levels should be seen as a key point in devising effective treatments.},
  author       = {Ulusoy, Ayse and Kirik, Deniz},
  issn         = {0014-4886},
  language     = {eng},
  pages        = {258--260},
  publisher    = {Academic Press},
  series       = {Experimental Neurology},
  title        = {Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease?},
  url          = {http://dx.doi.org/10.1016/j.expneurol.2008.04.026},
  volume       = {May 3},
  year         = {2008},
}